Abstract: Arsenic-based compounds are paradoxically both poisons and drugs. Glutathione transferase (GSTP1-1) is a major factor in resistance to such drugs. Here we describe using crystallography, X-ray absorption spectroscopy, mutagenesis, mass spectrometry, and kinetic studies how GSTP1-1 recognizes the drug phenylarsine oxide (PAO). In conditions of cellular stress where glutathione (GSH) levels are low, PAO crosslinks C47 to C101 of the opposing monomer, a distance of 19.9 Å , and causes a dramatic widening of the dimer interface by approximately 10 Å . The GSH conjugate of PAO, which forms rapidly in cancerous cells, is a potent inhibitor (K i 5 90 nM) and binds as a di-GSH complex in the active site forming part of a continuous network of interactions from one active site to the other. In summary, GSTP1-1 can detoxify arsenic-based drugs by sequestration at the active site and at the dimer interface, in situations where there is a plentiful supply of GSH, and at the reactive cysteines in conditions of low GSH.
Introduction
Glutathione transferases (GSTs; EC 2.5.1.18) are a key part of the antioxidant response system. 1, 2 Their principal mode of detoxification is through catalyzing the conjugation of target compounds to glutathione (GSH) as a first step in the removal of toxins from cells. In addition, GSTs can also protect cells by binding toxic compounds, through noncatalytic sequestration mechanisms. Due to the high expression levels of GSTs in many cells, this particular ligandin function may contribute to toxin resistance more significantly than previously considered. GSTs have been strongly implicated in various cancers; for example, in several tumor cell lines there is substantial overexpression of these enzymes following exposure to antitumor drugs. [1] [2] [3] Acquired resistance, which eventually arises in patients after an initial period of successful anticancer treatment, has been related in some cases to the presence of GST enzymes. 4 Arsenic is a human carcinogen causing cancers of the skin, lung, bladder, liver, and kidney after long-term exposure. Toxic exposure to arsenic is a serious health problem in some parts of the world where it occurs either naturally or as a pollutant. 5 Although arsenic is well-known for its properties as a human carcinogen, arsenicals have also been used as therapeutic agents for thousands of years. 6, 7 Up until the early 1900s arsenic was used as the primary antileukemic agent until it was replaced by radiation therapy and more modern chemotherapy. Arsenicals made a comeback in the early 1970s when they were used successfully for the treatment of acute promyelocytic leukemia (APL). Arsenic trioxide (As 2 O 3 , Trisenox) was approved for treatment of APL in 2000 for patients who fail to respond to other chemotherapy methods or have relapsed disease. 8 This recent success has prompted researchers to consider arsenic's application in the treatment of other malignant disorders including chronic lymphocytic leukemia, multiple myeloma, 9, 10 and solid tumors such as neuroblastoma, 11 gastric, 12 and cervical tumors. 13 Cells can develop tolerance to arsenicals [14] [15] [16] and a correlation between GSTP1-1 overexpression and development of resistance to arsenicals has been described by a number of workers. For example, the level of arsenic resistance in an arsenic-resistant mammalian cell line is correlated with expression levels of GSTP1-1, and GST inhibitors markedly decrease cell resistance to the metalloid. 17 It has been shown that the enzyme is directly involved in excretion of arsenic from cells. 18 Furthermore, acquired selftolerance to arsenic in chronically exposed cells is associated with increased expression of GSTP1-1 and multidrug resistance transporters. 19 Inhibition of the enzyme markedly increases arsenic accumulation and arsenic toxicity, indicating the enzyme's upregulation is critical for acquired tolerance in cells chronically exposed to arsenic. 19 GSTP1-1 has been shown to block As 2 O 3 -induced apoptosis in leukemia, prostate cancer and lymphoma cells. [20] [21] [22] In vivo studies have shown that GSH serves as a reducing agent for the conversion of arsenate to arsenite, and that GST activity is involved in the metabolism of arsenic by catalyzing the formation of arsenic-GSH conjugates. 23, 24 The tri-GSH conjugate As(GS) 3 , is recognized and pumped out of the cell by multidrug resistant pump 1. Leslie et al. 25 showed that GSTP1-1 was required for transport of As(III) (plus GSH) providing substantive evidence that the formation of As(GS) 3 might be catalyzed by GSTP1-1. The organic arsenical, phenylarsine oxide (PAO), is a membrane-permeable phosphotyrosine phosphatase inhibitor that is active in hematopoietic cells. 26 Several groups have reported the cytotoxic effects of PAO in hematological malignancies. [26] [27] [28] The cytotoxic effect of PAO is nine times higher than As 2 O 3 , and this toxicity does not weaken toward As 2 O 3 -resistant cell lines. 29 These results suggested that PAO may be a promising new agent for the treatment of APL, particularly for APL patients who are resistant and refractory to As 2 O 3 treatment. However, PAO's high toxicity and nonselectivity for cancer cells over normal cells are drawbacks to be overcome in any drug development program. Recently, an analog of PAO (4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid) has been tested in phase I clinical trials for solid tumors that are refractory to standard therapy. 30 It is now well-established that in human cancers, arsenic detoxification is performed by the GST/GSH detoxification system. However, the interaction of GSTP1-1 with arsenic-based drugs is surprisingly poorly characterized. Here we describe crystallography, X-ray absorption spectroscopy, mass spectrometry, mutagenesis, and kinetics of GSTP1-1's interactions with PAO. A crystal structure of PAO bound to GSTP1-1 in the absence of GSH shows the region corresponding to helix a2, which contains the C47 residue, is disordered, consistent with PAO interacting with this reactive cysteine and causing the displacement of this region from its usual helical conformation. Binding is associated with a dramatic opening of the V-shaped dimer cleft. Furthermore, the extended X-ray absorption fine structure (EXAFS) and crystallographic studies suggest that PAO can crosslink C47 of one monomer to C101 of the neighboring monomer. Kinetic studies reveal that the GSH adduct of PAO binds in the active site of the enzyme and is one of the most potent inhibitors of GSTP1-1 so far described in the literature. The crystal structure of the PAO complex, in the presence of GSH, reveals that PAO binds as a di-GSH-phenyl arsenic complex at the active site of the enzyme. In addition, PAO interacts at the dimer interface with C101 of either subunit resulting in the formation of a continuous network of interactions that spans from one active site to the other. This is the first report of a GSTP1-1 inhibitor that can simultaneously block known ligand binding sites in both the active sites and dimer interface. Overall, the structures reveal that GSTP1-1, in the presence of GSH, can detoxify PAO in two ways: by binding di-GSH-phenyl arsenic at the G-site and by sequestering PAO alone at the dimer interface. In the absence of GSH, detoxification occurs through binding to the two reactive cysteine residues, C47 and C101. The structures provide a basis for the development of GST inhibitors that block all these sequestration modalities.
Results
The di-GSH adduct of PAO is a potent inhibitor of GSTP1-1
In healthy and cancerous cells, GSH is present at millimolar concentrations. Thus we first explored how human GSTP1-1 recognizes PAO in the presence of its substrate GSH. In the presence of 1 mM GSH and substoichiometric amounts of PAO (0.1 mM) at pH 6.5, the PA(GS) 2 complex is rapidly formed in a few seconds (t 1/2 < 1 s). The complex is characterized by a typical UV spectrum with a maximum at 210 nm and a shoulder at 273 nm (e M 5 2500 M 21 cm 21 ) [ Fig. 1(A) ]. The instability constant of the complex (K inst ), calculated as described in Materials and Methods section, is 1.6 3 10 29 M 2 . When incubated with GSTP1-1, this compound behaves as a strong competitive inhibitor of GSTP1-1 toward GSH (K i 5 90 nM) ( Table I) . To verify the possible involvement of the two highly reactive cysteines (C47 and C101) 31 in the binding of the PA(GS) 2 complex, we measured the K i values of the corresponding serine mutants of these two residues. The study suggests no direct interaction occurs between the mutated residues and the complex (Table I ). In fact, the decreased affinity of the complex in these mutants is quantitatively similar to the loss of affinity for GSH in both mutants.
Mass spectrometry reveals two adducts in the GSTP1-1 PAO GSH complex
In the presence of GSH two reaction species with GSTP1-1 were observed by mass spectrometry: a minor species with mass of 458.58 Da and a major species of 765.33 Da (Supporting Information Fig.  S1 ). The former corresponds to a monoglutathionylated species of PAO whereas the latter corresponds to the diglutathionylated species of PAO.
Crystal structure of the GSTP1-1 PAO GSH complex reveals multiple binding sites
We determined the crystal structure of the enzyme in complex with PAO and GSH to a resolution of 1.5 Å . The structure reveals that PAO interacts with GSTP1-1 at two different sites [ Fig. 2(A,B) ]. In the Figure 1 . Kinetic studies of PAO binding to GSTP1-1. (A) UV absorption spectra of PA(GS) 2 complex. 1 mM GSH was reacted with variable amounts of PAO 33 lM (____), 66 lM (----), 100 lM (2222) in 0.1M potassium phosphate buffer, pH 6.5. The spectrum of PAO alone (100 lM) is also reported (2ÁÁ2ÁÁ2ÁÁ). (B) Binding of PAO to GSTP1-1 was followed on the basis of the quenching of intrinsic fluorescence at 344 nm (k exc. 5 295 nm). GSTP1-1 (1 lM) was incubated with variable amounts of PA(GS) 2 (from 3 to 60 lM) in 0.1M potassium phosphate buffer, pH 6.5 (258C).
[PAO] 05 5 28 lM; n H 5 1.85. Experiment was performed in triplicate (i.e., three different spectrophotometric determinations performed on three distinct samples). Error bars represent SEM. . One of the GSH ligands, GSH1, binds in the G-site in the same way, with the same interactions, as seen in other GST-GSH complexes. 32, 33 The second GSH ligand, GSH2, binds in the active site in a head-to-tail direction with respect to the first GSH ligand. The GSH in the GSH2 site has a higher average temperature factor for its terminal glutamyl moiety (39 Å 2 ) compared with the G-site GSH (21 Å 2 ) which reflects the increased flexibility of this moiety and the relatively few contacts it makes with the protein as indicated by incomplete electron density [ Fig. 2(C) ]. The glycyl carboxylate moiety forms a salt bridge with the side chain of Arg13, and there are numerous van der Waals interactions with Ile104 and Tyr108. The phenyl group of the arsenic complex stacks between the aromatic rings of Phe8 and Tyr108 (distance between centroids of 4.5 Å and 6 Å , respectively) as well as forming van der Waals interactions with the main chain of Gly205 and the side chain of Val10 [ Fig. 2(C) ]. The arsenic atom is covalently bound through the sulfur atoms of the two GSH molecules, as well as the phenyl ring, and is within vicinity of the hydroxyl of Tyr108 (3.2 Å ). GSH2 makes a water-mediated interaction with Asp98 from the other subunit. GSH1 makes water-mediated interactions with residues such as Pro53, Gln64, Asn66, and Glu97 in addition to the usual protein interactions seen in other GSH bound GST structures, (Supporting Information Fig. S2 ). Two arsenic binding sites were also identified at the dimer interface, covalently bound to C101 of each subunit [ Fig. 2(A,B) ]. Reaction of PAO with a single thiol group would lead to a phenylhydroxyarsene complex. There was some additional electron density attached to the arsenic peaks that was modeled as the phenyl moieties. The location of the hydroxyl was not well-defined so was not modeled in this structure. The extensive water network that is normally observed at the dimer interface in other GSTP1-1 structures is disrupted by binding of PAO. At occupancy of 0.6, the average temperature factor of the arsenic ions refined to 26 Å 2 , similar to that of the C101 thiols (average of 28 Å 2 ). The arsenic ions form a 2.6 Å arsenic-sulfur bond with the thiol of C101 and are also within 3.0 Å of the carboxylate group of the glycyl moiety of GSH2 (Fig. 2) . Binding of PAO to GSTP1-1 in the absence of GSH
In stressed cells, the levels of GSH can be very low so we examined how GSTP1-1 interacts with PAO at low GSH concentrations. Binding of PAO to GSTP1-1 was followed on the basis of the quenching of intrinsic fluorescence of the protein [ Fig. 1(B) ]. Interestingly, the isothermic binding is strongly cooperative with an Hill coefficient of 1.85 and a [PAO] 0.5 5 28 lM (Table I ). We also evaluated the possible involvement of C47 or C101 on the binding of PAO. After replacing each of these residues separately with serine, the protein was still found to bind to PAO in a strongly cooperative process (n H 5 1.87) ( Mass spectrometry reveals major and minor metalloid binding sites in the PAO only complex
In the absence of GSH several reaction products were observed, with one major species showing an increase in the deconvoluted mass of approximately 167 Da. This mass would be consistent with one phenylhydroxy-arsene-Cys complex per monomer. A minor species of 334 Da per monomer was observed and corresponds to two phenylhydroxy-arsene-Cys complexes per monomer. The kinetic (see above) and crystallographic studies (see below) are consistent with the major site of PAO reaction being at C47 and the minor site at C101. C47 has been shown previously to be the most reactive cysteine in apo GSTP1-1.
31
Crystal structure of the GSTP1-1 PAO complex in the absence of GSH reveals metalloid binding at the dimer interface and displacement of helix a2
In the absence of GSH, electron density for the arsenic adduct is evident at the dimer interface, albeit at a low occupancy, bound to the thiol of C101 of each subunit [ Fig. 3(A) ]. The arsenic atoms refined to occupancies of 0.3 with an average temperature factor of 36 Å 2 , close to those of the C101 thiols (average of 38 Å 2 ). Interestingly, these sites are on the opposite side of the C101 thiols to that seen for the same peaks in the structure with GSH described above [ Fig. 3(A,B) ]. No electron density was evident for the phenyl ring or the hydroxy ligand, so they were excluded from refinement. The usual water network observed at the dimer interface in other GSTP1-1 structures is severely disrupted by binding of PAO, as was observed in the GSH-bound structure.
Strikingly, there is no electron density for the region corresponding to helix a2, (residues 35-50) suggesting it has become highly mobile and possibly disordered [ Fig. 2(A,C) ]. This region includes C47 and the kinetic studies showed that PAO reacts with this residue in the absence of GSH. In contrast, the same region in the GSH-bound structure described above is well-ordered, consistent with published kinetic studies that C47 becomes inaccessible in the presence of GSH. 31 Thus we assume the absence of density in this region is a consequence of the G-site being empty and PAO binding to C47. The C-terminal end of helix a2 includes Tyr49, a residue that has been described as a "key" that fits into a hydrophobic pocket (the "lock") of residues contributed from the neighboring subunit [ Fig.  2(A) ]. 32 Mutational studies of Tyr49 show that it is a critical residue for stability of the GSTP1-1 dimer. 34 We visualize for the first time the consequences of removing the key from the lock: the cleft at the dimer interface has widened markedly with an increase in the separation at the tip of the helical towers of approximately 8 Å . Superposition of the individual monomers onto the corresponding monomers in the GSH-bound structure described above indicates no significant changes in the monomeric structures (r.m.s.d. of $0.3 Å ). Superposition of one monomer of the PAO complex onto the published wild-type GSTP1-1 GSH complex structure (PDB id: 5GSS 33 ) reveals a rotation of approximately 108 of the second monomer with respect to the first, pivoting at the base of the helical tower [ Fig. 3(D) ]. Superposition of the GSH-bound and GSH-absent dimers reveals that while the residues at the base of the dimer superimpose closely, the upper half of the dimer has separated. The distance between the C101 carbon alpha atoms has increased from 7.8 Å in the GSH-bound structure to 11.2 Å in the GSH-free structure. We confirmed this observation by collecting a further three data sets, each from one crystal, of the GSH-free PAO complex and the widening of the dimer interface to the same degree was consistent throughout.
Crystal structure of the GSTP1-1 PAO complex from crystals grown in the absence of GSH and subsequently soaked in GSH
To determine if binding of GSH to the active site was sufficient to re-stabilize helix a2, which forms one wall of the G-site, we took a PAO soaked crystal, in the absence of GSH, after 2 days, and reintroduced GSH. This crystal was from the same drop as the crystal used for the PAO structure described above. To our surprise, back-soaking this crystal in GSH for 5 days restored the structure of the disordered helix, including the "lock-and-key" and restabilized the interaction between the monomers, resulting in a distance between the tips of the helical towers identical to that observed in published GSTP1-1 structures. C47 and C101 are no longer modified, presumably because the excess GSH competed with PAO at that site. Furthermore, many of the critical waters that are usually observed in the dimer interface of other GSTP1-1 structures are again observed. This back-soaked structure has the di-GSH-phenyl arsenic species bound at each active site, each with an occupancy of 0.6 and average temperature factor of 25 Å 2 .
Crystal structure of apo GSTP1-1
We next wanted to explore whether the absence of helix a2 and the widened interface were due to the absence of ligand in the G-site as such ligands are thought to stabilize the helix which forms one wall of the site. Although apo GSTP1-1 structures have previously been reported they were generated from crystals that were soaked in ligands that were not visible in the electron density maps. As it is possible that the ligands were still bound but disordered, we decided to solve an apo GSTP1-1 structure from crystals that were not soaked in any ligand. The structure shows good electron density for all regions of the protein, including helix a2 and the lock-andkey, and there is an extensive network of waters visible at the dimer interface and in the active sites. Although helix 2 can be observed, an analysis of temperature factors shows this region in both monomers is one of the most mobile regions in the structure in accord with published solution studies.
35-37
The V-shaped dimer cleft resembles that seen in published GSTP1-1 structures. Thus the disappearance of helix a2 and the widened cleft seen in the PAO complex is not due to absence of ligand in the active site.
EXAFS studies reveal that PAO binding to GSTP1-1 in the absence of GSH results in the formation of two AS-S bonds
We undertook X-ray absorption spectroscopy (XAS) studies to determine the ligand environment of the arsenic binding sites in the enzyme. This study Table S1 is shown as the dotted trace in both k and R space.
could only be done in the absence of GSH since PAO reacts with GSH rapidly in solution. Our crystallographic, mass spectrometry, and kinetic studies, performed in parallel with the XAS studies, revealed that PAO could react with two sites (C47 and C101) on the enzyme. X-ray absorption near edge spectroscopic data [ Fig. 4(A) ] showed that the oxidation state of arsenic remains as As(III) when PAO is bound to the enzyme. The white line peak energy was found to be identical to that of aqueous As(GS) 3 , but a comparatively lower peak intensity indicated a lower symmetry environment, consistent with a 2S,1C coordination shell. 38 Curve fitting analysis of extended X-ray absorption fine structure data (EXAFS) showed that arsenic was bound to two sulfur donor ligands at a bond distance of 2.24 Å in the GST-PAO complex (Supporting Information Table S1 ), with a model containing three AsAS sulfur interactions producing a significantly greater fit error. Attempts to include an As-C fit component were complicated by strong EXAFS cancellation over the full data range with the longer distance As-S component, producing a characteristic minimum in the EXAFS Fourier transform at approximately 2 Å [ Fig. 4(B) ]. Nonetheless, a fit which included a fixed Debye-Waller factor for the AsAC component produced an AsAC bond distance of 1.93 Å which is consistent with the median distance (1.96 Å ) for such a bond in the eighty examples of similar coordination environments (2S,1C-phenyl) found in the Cambridge crystallographic database.
The EXAFS data are consistent with PAO forming a crosslink between C47 and C101. Inspection of the structure suggests the crosslink is most likely between monomers and the location of the arsenic anomalous signal on the opposite side of C101 to that observed in PAO GSH complex also supports this interpretation [ Fig. 3(A-C) ].
Discussion
PAO is considered a promising agent for treating certain types of leukemia and solid tumors that are resistant to other anticancer drugs, with an analog currently in human clinical trials. 30 However, in cancer cells PAO is readily attacked by GSH and protein thiols such as those in GSTP1-1, a detoxifying enzyme that is overexpressed in many types of cancer cells at millimolar concentrations. 1,2 Studies in yeast suggest that arsenic is mainly proteinbound in acute exposure situations whereas it is mainly GSH-bound after long-term exposure. 39 Thus GSTP1-1 may be a major cause of arsenic drug inactivation in human cancer cells. We show here that the GSH adduct of PAO is a potent inhibitor of GSTP1-1 with a K i of 90 nM. We further show that the parent molecule, PAO, can react with C47 and C101 of the enzyme (Table I ).
The crystal structure of GSTP1-1 complexed to PAO, in the presence of GSH, reveals four arsenic ligands bind to the enzyme, connected to each other via an extensive network of interactions [ Fig. 2(A) ]. Bond lengths between the arsenic atom and the GSH thiol atoms are approximately 2.4 Å , which is in accordance with the expected bond lengths for this interaction. 40 This structure is very similar to the published wild-type GSH complex structure (PDB id: 5GSS 33 ) with a r.m.s deviation in carbon a positions of 0.3 Å for 414 residues. Despite the accommodation of an additional GSH ligand, as well as the phenyl-arsenic moiety in the active site, no significant movements are observed for any of the active site residues. In the absence of GSH, the crystal structure shows that PAO binds to the C101 ligands at the dimer interface with an arsenic-sulfur bond distance of 2.4 Å [ Fig. 3(A) ]. The enzyme appears less reactive with PAO in the absence of GSH, suggesting that the GSH-mediated interactions with the arsenic-bound C101, observed in the PAO-GSH complex, might facilitate and stabilize binding of arsenic at this site. Although C47 is not observed in the crystal structure our kinetic and mass spectrometry studies are consistent with PAO binding at this residue also. Mass spectrometry revealed a major reaction species in the absence of GSH that corresponds to one PAO per GST monomer and a second reaction species in the sample with two PAO per GST monomer. The crystallography data are consistent with C47 being the major site of PAO binding. EXAFS showed that arsenic was bound to two sulfur donor atoms at 2.2 Å and one carbon at 1.9 Å when PAO was incubated with GST in the absence of GSH (Fig.  4) , indicating that the reaction resulted in the loss of the oxido ligand from PAO, but the retention of the phenyl group. Taken together the data support an intermonomer crosslink between C47 and C101 [ Fig. 3(C) ].
The most remarkable feature of the GSH-free PAO complex structure is the increase in width of the water-filled cleft at the dimer interface. Normally the distance between the a carbon atoms of residue 113, located at the top of the helical towers, is 22.3 Å but in the GSH-free PAO complex structure this distance is 28.2 Å [ Fig. 3(D) ]. 33 The change in the dimer interface appears specific for PAO as the ligand was introduced by soaking pre-formed GST crystals using the same protocol that has been used previously for numerous other GST ligands, none of which resulted in a change to the dimer interface. 33, [41] [42] [43] [44] [45] Furthermore, the effect appears to be associated with PAO binding of C47 as binding at C101 in the presence of GSH did not cause any change to the dimer interface. This movement at the dimer interface is probably the cause of the strong cooperativity observed during PAO binding either to wild-type or to the single Cys mutants. This homotropic cooperative interaction, mimics the one produced by 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol when it binds to GSTP1-1 in the absence of GSH 46 and is likely made possible by the lock-and-key motif present at the dimer interface. 34 A surprising feature of the GSH-free PAO complex is the absence of electron density for helix a2 (residues 35-50). Previously published "apo" human GSTP1-1 structures were derived from wild-type crystals soaked in ligands expected to bind in the active site giving rise to the doubt that the G-site was truly empty. Thus we decided to determine a new apo structure that revealed an intact helix a2. It thus seems likely that the disorder of helix a2 is associated with chemical modification of C47, which is known to be accessible only in the apoezyme. 31 Disruption of helix a2 by C47 modification with the more bulky PAO leads to withdrawal of the key residue, Tyr49, from its hydrophobic lock and subsequent weakening of the dimer interface. Others have shown that mutation of Tyr49 to alanine leads to unstable GST dimers. 34 Remarkably, the major disruptions caused to the GST structure could be reversed by back soaking GSH into crystals that were previously treated with PAO only. The arsenic-based complexes presented here highlight the necessity to design and develop a novel drug that inhibits the enzyme at both the active site and the dimer interface to be as effective and optimal as possible. The GSTP1-1 PAO GSH structure described here provides a framework for the design of such compounds.
Materials and Methods

Materials
Wild-type GSTP1-1 and mutants were expressed in E. coli and purified as described previously. 47 Stability of PA(GS) 2 complex and kinetic studies with GSTP1-1
The instability constant K inst 5 ½GSH 2 ½PAO ½PAðGSÞ 2 was calculated by adding step-by-step GSH to a fixed concentration of PAO (60 mM) in potassium phosphate buffer 0.1M pH 6.5 and recording absorbance at 273 nm to quantify the amount of the formed complex. Inhibition experiments of PA(GS) 2 on GSTP1-1 were performed by incubating 1 lg of enzyme in 0.1M potassium phosphate buffer pH 6.5 (258C) with variable amounts of GSH at fixed 1 mM CDNB at three different fixed PA(GS) 2 concentrations. Reaction rates were recorded at 340 nm.
Fluorescence study
The quenching of intrinsic fluorescence of enzyme (excitation wavelength 295 nm, emission wavelength 344 nm) was measured in a single photon counting spectrofluorometer Fluoromax-4 Horiba, after the addition of variable amounts of PAO and enzyme. Crystallization GSTP1-1 was expressed, purified, and crystallized as described previously. 44 Cocrystallization experiments were not attempted because dithiothreitol (DTT), an essential ingredient for crystallization, would react with PAO. (GST P1-1 crystals only grow in reducing conditions, likely due to the two highly reactive surface cysteines in each monomer of the GST dimer). PAO (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) to make a 20 mM stock solution. Aliquots of the stock were added to a reservoir solution and diluted to a final concentration of 0.2-2.0 mM PAO. Crystals were transferred to 2 lL drops and left to soak for periods of several hours to a week.
Structure determination
Unless otherwise stated all data sets were processed with MOSFLM 48 and scaled with the program SCALA. 49 The structures were solved by molecular replacement using PHASER 50 with a model of GSTP1-1 complexed to GSH (PDB id: 5GSS) as a probe. Model building was done with COOT, 51 interspersed by rounds of positional and isotropically restrained B-factor refinement using Phenix Refine. 52 A summary of the data collection and refinement statistics and molprobity 53 analysis for all structures, including their quality relative to other structures at similar resolutions, is provided in Supporting Information Table S2 .
XAS studies
Results from the mass spectrometry suggested that interaction of PAO with the protein at a single site per monomer was optimal at 2:1 ratio of PAO for 10 h. XAS data were recorded at 20 K on beamline 20B at the Photon Factory (Tsukuba, Japan). K-edge As XAS were measured in fluorescence detection mode using a 36-element Ge monolithic pixel array detector (Eurisys).
Mass spectrometry studies
Reaction mixtures were analyzed by electrospray mass spectrometry on an Agilent 6510 Q-TOF LC/ MS (Bio21 Institute, Melbourne University).
Statistical Analysis
All experiments were performed in triplicate (i.e. on three distinct samples). Errors are given as SEM. Kinetics and spectroscopic data were analyzed by GraphPad Prism software (La Jolla, CA).
Accession Numbers
The models have been deposited in the Protein Data Bank (http://www.rcsb.org/pdb/) under the accession numbers 5DCG (apo GSTP1-1), 5DAL (PAO-GSH complex), 5DAK (PAO complex, no GSH), and 5DDL (PAO complex soaked into crystals and back-soaked with GSH).
